About gsk plc - GSK
GSK At a Glance
| Phone | 44-20-8047-5000 | Revenue | 37.70B | |
| Industry | Pharmaceuticals: Major | Net Income | 6.13B | |
| Sector | Health Technology | 2023 Sales Growth | 4.37% | |
| Fiscal Year-end | 12 / 2024 | Employees | 70,212 | |
| View SEC Filings |
GSK Valuation
| P/E Current | 21.522 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 12.257 |
| Price to Sales Ratio | 2.021 |
| Price to Book Ratio | 4.417 |
| Price to Cash Flow Ratio | 9.654 |
| Enterprise Value to EBITDA | 7.955 |
| Enterprise Value to Sales | 2.436 |
| Total Debt to Enterprise Value | 0.25 |
GSK Efficiency
| Revenue/Employee | 536,934.944 |
| Income Per Employee | 87,246.617 |
| Receivables Turnover | 3.995 |
| Total Asset Turnover | 0.511 |
GSK Liquidity
| Current Ratio | 0.885 |
| Quick Ratio | 0.624 |
| Cash Ratio | 0.246 |
GSK Profitability
| Gross Margin | 70.074 |
| Operating Margin | 23.058 |
| Pretax Margin | 20.011 |
| Net Margin | 16.249 |
| Return on Assets | 8.302 |
| Return on Equity | 41.163 |
| Return on Total Capital | 15.32 |
| Return on Invested Capital | 17.593 |
GSK Capital Structure
| Total Debt to Total Equity | 134.997 |
| Total Debt to Total Capital | 57.446 |
| Total Debt to Total Assets | 30.536 |
| Long-Term Debt to Equity | 113.921 |
| Long-Term Debt to Total Capital | 48.478 |
Gsk Plc in the News
With popular asthma inhaler now discontinued, what other options do patients have?
Glaxo Smith Kline (GSK) announced in May that Flovent HFA, a metered-dose inhaler, as well as Flovent Diskus, a dry powder inhaler, would be discontinued as of Dec. 31, 2023. Experts weigh in.
India set to release newly developed cervical cancer vaccine soon
The Serum Institute of India (SII) has recently announced that they have successfully developed the world's first cervical cancer vaccine, which will soon hit shelves soon.
Western drugmakers are still providing medicines to Russia
Western health care companies continue supplying medicine, vaccines and medical equipment to Russia.
Biden pushes Congress to allow Medicare to negotiate drug prices
President Biden is set to lay out his vision Thursday for reducing the high cost of prescription drugs, and is expected to push Congress to pass legislation that would allow Medicare to negotiate drug prices for millions of Americans.
Possible new Sanofi-GSK coronavirus vaccine showing promise in trials, companies say
A possible new coronavirus vaccine candidate produced by Sanofi and GSK (GlaxoSmithKline) that uses the human body’s own antigens to neutralize antibody responses for people who have already recovered from the illness, has completed Phase 2 trials, the companies said Monday.